Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme Reports Fourth Quarter And Full-Year 2018 Results

PR Newswire February 21, 2019

The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan

Benzinga.com  February 21, 2019

The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Benzinga.com  February 15, 2019

Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call

PR Newswire February 7, 2019

argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

GlobeNewswire February 4, 2019

Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth

GlobeNewswire December 27, 2018

Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

PR Newswire December 26, 2018

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. – HALO

GlobeNewswire December 3, 2018

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cheetah Mobile Inc. - CMCM

Canada NewsWire November 29, 2018

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Tenaris, S.A. (TS)

GlobeNewswire November 29, 2018

The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

Benzinga.com  November 27, 2018

Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival

PR Newswire November 26, 2018

Report: Exploring Fundamental Drivers Behind Entergy, BLACKLINE INC, HollyFrontier, Hill-Rom, Apache, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 8, 2018

Halozyme Reports Third Quarter 2018 Financial Results

PR Newswire November 6, 2018

Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications

PR Newswire November 6, 2018

Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties

PR Newswire October 30, 2018

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

PR Newswire October 25, 2018

Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress

PR Newswire October 22, 2018

Halozyme To Host Third Quarter 2018 Financial Results Conference Call

PR Newswire October 10, 2018

Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment

PR Newswire October 4, 2018